According to the World Health Organization, cancer is the second leading cause of death globally and was responsible for nearly 9 million deaths in 2015. Although some types of cancer may be hereditary, most cancers develop as a result of other causes. Minimizing exposure to risk factors reduces the incidence of cancer, while utilizing improved methods of early detection improves the odds of successful treatment, yet new therapies are urgently needed. Therefore, Sanofi desires partners to find and develop novel targets in the area of oncology.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.
Cancers are characterized by abnormal cell growth and appropriate treatment is dependent on the type and stage of the disease. One strategy for the development of cancer therapies resides on the notion that tumors are heterogeneous in their origin and in their genetic background and that effective treatment needs to be tailored to a specific patient subgroup. This so called precision medicine has led to a few bright spots in the fight against cancer, for example therapies targeted against the human epidermal growth factor receptor 2 protein (HER-2) in certain breast and stomach cancers that overexpress HER-2 or therapies targeted against the BCR-ABL fusion protein, that is present in some leukemias. While these precision medicines are well tolerated and highly efficacious in their specific tumor context, in most cases, tumors eventually become resistant to therapy and the patient will no longer respond to treatment. Also, for most tumor types, suitable precision medicine treatment remains to be identified and the actual proteins driving cell growth and survival in the different genetic backgrounds are not known. Here, Sanofi desires partners to find and develop novel and actionable targets, whose inhibition will block tumor growth in molecularly well-defined patient populations.
This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (up to 5 pages, including supporting non-confidential information and contact details) to be evaluated by Sanofi with a goal of establishing a collaborative partnership. Upon completion of the evaluation, Sanofi may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed upon time frame.
[NOTE: Only proposals from Solvers who have the ability to work as the collaboration partner will be considered. Furthermore, Sanofi may elect to make up to two awards of $5,000 each for the top 2 proposals.]
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 22, 2017.
Late submissions will not be considered.
ABOUT THE SEEKER
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur, and Consumer Healthcare. For more information, visit en.sanofi.com/.
What is an eRFP Challenge?
eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.
After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.
This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.